Gappify and CFGI Announce Strategic Partnership
BOSTON, Aug.
CFGI Announces Expansion Into the UK
LONDON, July 26, 2023 — CFGI, a portfolio company of Carlyle and CVC, announces its expansion into the U.
Oculis Announces Public Listing After Completing Business Combination Between European Biotech Acquisition Corp. And Oculis SA
CFGI’s Capital Markets team assisted Oculis Holding AG (“Oculis”) with its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp.
Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market
CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.
Senti Biosciences Completes Merger With Dynamics Special Purpose Corp.
CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.
BCP Raptor Holdco LP Completes Reverse Merger With Altus Midstream Company
CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.
2021 Year in Review
2021 was a year of tremendous change and growth for CFGI.
Capital Markets Advisory: 2021 Year in Review
2021 was an exciting year of growth for CFGI, which included a new partnership with CVC Capital Partners, one of the world’s largest private equity firms.